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consistent with a study in normals in which increasing doses of
norepinephrine produced increased randomness of heart rate
patterns (2). This hypothesis could easily be tested using multiple
methods. One would be to plot the HRV power spectrum. If there
were, indeed, an increase in vagal modulation of heart rate, there
would be a clear increase in the size of a clearly seen peak in the
high-frequency band. If an increase in randomness occurred, any
increase in high-frequency power would be associated with an
increasingly broad and abnormal-looking peak.
Alternatively, the Poincare´ plot (a plot of each normal-to-
normal interval vs. the next) could be generated. Increased ran-
domness would be associated with an increasingly complex-
looking plot (3). Finally, nonlinear HRV indices could be
calculated. The calculation of the short-term fractal scaling expo-
nent (4) would normally require about 1,000 beat-segments of
data. The ratio of the axes of an ellipse fitted to the Poincare´ plot
(SD12) could be calculated for the same 5-min segments that were
used for HRV. Increasing values of SD12, or decreasing values of
the short-term scaling exponent, would be consistent with increas-
ing randomness, rather than increased levels of autonomic modu-
lation of the heart. Indeed, this technique has previously been
applied to ventricular tachycardias, and increased SD12 was found
to precede arrhythmic events (5).
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We thank Dr. Stein for her interest and comments. Although we
would like to study nonlinear methods in our patients, this task was
prohibitive in the time frame required for this response. We
appreciate the suggestions and will explore our data using these
methods in the future.
Dr. Stein suggests that postoperative patients behave similarly
to healthy volunteers in whom increased randomness of the
heart-period signal was attributed to increasing doses of norepi-
nephrine (1) and that the increases in both time- and frequency-
domain parameters of heart rate variability (HRV) observed in our
study do not represent vagal resurgence (2). We disagree with this
hypothesis for several reasons.
First, in a study of patients undergoing major thoracic or
abdominal surgery, we showed persistent downregulation and
desensitization of the lymphocyte beta-adrenergic receptor/
adenylyl cyclase system, which correlated with decrements in time-
and frequency-domain indices of HRV throughout the first week
after surgery (3). These changes occurred in the absence of change
in perioperative epinephrine or norepinephrine levels.
Second, to suggest that our atrial fibrillation (AF) patients (n 
48) had a significantly different perioperative neurohumoral re-
sponse than did that of controls (n  48) matched for age, gender,
and identical operation, appears unlikely. Finally, the HRV re-
sponse seen in our control group was very similar to that seen in
other patients undergoing major thoracic surgery, supporting the
presence of parasympathetic withdrawal and not resurgence (4).
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Measurement of Circulating Vascular
Endothelial Growth Factor in Obese Subjects
I read with interest the report by Rehman et al. (1) evaluating the
circulating levels of hepatocyte growth factor (HGF) and vascular
endothelial growth factor (VEGF) in obese subjects. Although the
investigators should be congratulated by their results on the study
of HGF, I would like to underline some methodological concerns
regarding the measurement of VEGF levels.
Serum VEGF is not a suitable indicator of circulating extracel-
lular VEGF levels at the time of sampling; VEGF is stored in the
-granules of platelets and is released during blood clotting. As a
consequence, VEGF level in the serum is several-fold higher than
that in matched plasma samples (2,3). In plasma, platelet degran-
ulation is minimized by adding anticoagulants to the blood
samples; in particular, CTAD (citrate, theophylline, adenosine,
dipyridamole) plasma is recommended for the measurement of
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circulating extracellular VEGF (4). The investigators (1) stated
that “serum was separated after coagulation,” but they did not
report the interval between venipuncture and separation of serum
from blood cell; this interval should be standardized and declared.
In serum, VEGF concentrations increase in a time-dependent
manner (5). In a clinical situation, where blood samples are taken
and left for variable times before processing, the contribution from
the clotting process would make the measurement unreliable (5).
Allowing the whole blood sample to clot for between 2 and 6 h
before serum is collected reduces time-dependent, nonuniform
release of VEGF (6). In addition, the researchers did not report the
conditions of processing (centrifugal force and the length of
centrifugation), which are relevant and should be standardized.
Finally, a direct correlation between platelet counts and serum
VEGF has been described (6). When serum is used for the
measurement of VEGF, it is advisable to correct the results for
variations in platelet count and platelet size (3).
In conclusion, meticulous standardization of sampling is a
mandatory step in studies on blood VEGF levels. The investiga-
tors’ conclusion that “serum VEGF levels were not significantly
elevated in obese versus lean subjects” cannot be justified on the
basis of the data presented.
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We would like to thank Dr. Ferrero for the comments regarding
our study, which demonstrated that obesity was associated with an
increase in serum hepatocyte growth factor (HGF) levels (1). Our
study also showed a nonsignificant trend toward higher vascular
endothelial growth factor (VEGF) levels in the serum of obese
subjects. As Dr. Ferrero correctly points out, the time between
collection of blood samples and the time when the serum is
centrifuged can affect the concentrations of growth factors like
VEGF. We are not aware of any clear directional bias in our study
related to serum collection that would have resulted in low levels of
serum VEGF in obese subjects and thus masked higher circulating
VEGF levels. However, VEGF levels did demonstrate marked
interindividual variability, and this may have contributed to the
absence of a statistically significant difference of VEGF levels
between obese and nonobese subjects. It is quite possible that
serum HGF levels may be more robustly associated with obesity,
whereas serum VEGF levels may be a reflection of not just obesity
but also other co-morbidities and factors like the serum clotting
time.
Furthermore, a more recent study was indeed able to show that
serum VEGF levels are associated with obesity (2). Interestingly,
the researchers in that study found that visceral fat area showed a
better correlation with circulating VEGF levels than did body mass
index. This may reflect a greater contribution of visceral fat to
circulating VEGF levels than other fat tissues.
Finally, we believe that the association between obesity and
vascular growth factor is an exciting and rapidly growing area of
research, and it will continue to enhance our knowledge of how
obesity can affect both the vasculature and atherosclerosis.
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